PyInvesting

Market research

2616.HK CStone Pharmaceuticals

HK HKD Healthcare

Latest close

5.68 —

As of Nov 20, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
9B
P/E ratio
Not available
Analyst target
15.5791
Dividend yield
Not available
Beta
0.29

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

CStone Pharmaceuticals is currently in a long term uptrend where the price is trading 42.3% above its 200 day moving average.

From a valuation standpoint, the stock is 92.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.

Its net income has increased by 48.7% to $-550M since the same quarter in the previous year.

Finally, its free cash flow grew by 5.6% to $-330M since the same quarter in the previous year.

Based on the above factors, CStone Pharmaceuticals gets an overall score of 4/5.